Summary: A major neuroregeneration study overturns a long-held assumption by showing that axon damage in the human central nervous system, previously considered irreversible, can be reversed. The work uses patient-derived 3D stem cell organoid circuits cultured for more than a year to model corticospinal development and identify a genetic maturity program that shuts down axon regrowth in mid-gestation. The team also found a licensed hormone drug, lynestrenol, that can reactivate axon regeneration in mature human neurons in this model.
Key Facts
- The paralysis block discovered: During human development, neurons extend axons that form long-range pathways carrying movement commands from the brain to the spinal cord. Medical consensus has long held that central nervous system (CNS) neurons lose their intrinsic ability to regrow, making paralysis from spinal injury and certain neurodegenerative diseases effectively permanent. This study shows that loss of growth capacity is a programmed developmental change rather than an unavoidable adult limitation.
- Human-derived functional circuit: Researchers used human stem cells to grow separate cortical and spinal organoids in a dish. Over time, cortical axons extended across the gap and formed functional connections with the spinal tissue, driving contractions in small attached muscle clusters—creating a working, three-dimensional human corticospinal circuit in vitro.
- Developmental timing: the day 150 shift: By maintaining the model for over a year, the team pinpointed a precise developmental window. Until about day 150—equivalent to mid-trimester human pregnancy—axons could robustly regrow after injury. Past that point, as neurons matured and formed synapses, axon regrowth capacity fell sharply and became persistently low.
- A genetic maturity switch: Single-cell gene expression analyses identified an integrated transcriptional program that acts as a binary switch, limiting axon elongation as projection neurons mature. Interfering with key regulators of this network reverted mature neurons toward a more growth-permissive state and restored their capacity to extend axons.
- Drug repurposing: lynestrenol: A drug screen targeting components of the maturation-associated network highlighted lynestrenol, a hormonal medication used for menstrual disorders and contraception. Applied to injured, mature human neurons in the model, lynestrenol enhanced axon regrowth, providing a proof of principle for pharmacological reactivation of human axon repair.
- Human models reduce reliance on animal data: Much of the existing nerve repair literature relies on rodent experiments, but rodent neurons differ from human neurons in key respects. Human organoid-based systems offer a closer proxy for patient biology and help bridge gaps between animal findings and potential human therapies while reducing animal use.
Source: University of Cambridge
Cambridge researchers have built miniature, connected brain–spinal cord circuits in the laboratory and used that system to reveal when and why axon regeneration ends—and how it can be restarted.
During prenatal development, neurons readily extend axons that connect the brain to spinal motor circuits. In adult humans, however, injury or disease frequently leaves these axons unable to regrow, producing lasting impairment such as paralysis or loss of limb control. Understanding whether that inability is an intrinsic, programmed property of human neurons and whether it can be reversed has been a central challenge.
The Cambridge team built on prior cortical organoid methods to grow paired cortical and spinal organoids from human patient‑derived stem cells. By keeping the tissues spatially separated in culture, the researchers allowed cortical axons to navigate and form directed connections with spinal tissue. Over months these axons established functional circuitry and drove contractions in micro-muscle aggregates, demonstrating physiological connectivity.
Tracking that system over long timescales revealed a clear developmental inflection. Before day 150, injured axons regrew effectively; after day 150, growth capacity fell sharply as neurons activated a synaptogenic, maturation-associated transcriptional program. Single-cell transcriptomics and computational analyses pinpointed the genes and regulators responsible for this transition.
Targeting those regulators chemically and genetically reversed the maturation signature and reinstated axon growth in mature human neurons in the dish. A focused screen of existing compounds identified lynestrenol as a repurposable molecule that interacts with the identified pathway and significantly enhanced axon regrowth in injured models. While lynestrenol may not be the final therapeutic, it provides compelling evidence that pharmacological reactivation of human axon growth is feasible.
Re-establishing axon growth is only one step toward restoring lost function; subsequent work must show that regrown axons can find appropriate targets and rebuild precise circuitry across the CNS. Nevertheless, these human organoid-derived systems offer a powerful platform for testing human-specific mechanisms and candidate treatments for spinal cord injury, motor neuron disease, and demyelinating conditions such as multiple sclerosis.
Senior author Dr András Lakatos emphasizes that the findings reveal a developmental, reversible brake on regeneration rather than an immutable adult deficiency. The organoid model helps translate discoveries from animal studies into human biology and supports efforts to reduce reliance on nonhuman experiments.
Funding: UK Research and Innovation, Medical Research Council, and Spinal Research.
Key Questions Answered:
A: The study shows a programmed shutdown occurs during development. Around the mid‑trimester equivalent (about day 150 in this model), a genetic switch reduces a neuron’s intrinsic ability to extend axons. That built‑in change prevents efficient regrowth after adult injury.
A: After mapping the maturation-associated gene network, researchers screened drugs that modulate that program. Lynestrenol emerged as a compound that can shift the neuronal transcriptional state toward one that supports axon extension, allowing mature human neurons in the model to regrow axons after injury.
A: Not immediately. The result is a proof of concept showing human axons can be pharmacologically reactivated in vitro. Major challenges remain: ensuring regrown axons reconnect accurately, translate to safe, effective in vivo therapies, and demonstrate functional recovery in patients.
Editorial Notes:
- Edited by a Neuroscience News editor.
- Journal paper reviewed in full by staff.
- Additional context added by the editorial team.
About this neurology and spinal cord injury research news
Author: Fred Lewsey
Source: University of Cambridge
Contact: Fred Lewsey – University of Cambridge
Image: Image credited to Dr András Lakatos
Original Research: Open access. “A human corticospinal organoid-slice connectoid model informs enhancer strategies for post-injury axon regrowth” by George M. Gibbons et al., published in Cell Reports. DOI: 10.1016/j.celrep.2026.117399
Abstract
A human corticospinal organoid-slice connectoid model informs enhancer strategies for post-injury axon regrowth
Axon elongation in the mammalian central nervous system declines during development, limiting regenerative capacity after birth. Intrinsic regulators of this process are promising therapeutic targets because immature axons can regrow in otherwise non‑permissive tissues. The timing and mechanisms of cessation of axon growth in the human CNS have been unclear. This study describes a three‑dimensional human corticospinal motor organoid‑slice connectoid platform that models developmental axon elongation and its subsequent restriction. Cortical and spinal slices form functional connections while remaining spatially segregated, enabling cortical cell‑type specific analysis. Single‑cell transcriptomics, computational analysis, axon regrowth assays, and live imaging identify transcriptional shifts that reduce axon growth in maturing human cortical projection neurons. The decline can be reversed using compounds, including repurposed drugs, that target the maturation‑associated transcriptional state and promote post‑injury axon repair.